Hikal (NSEI:HIKAL) - Aktienkurs, Nachrichten und Analyse

HIKAL Aktienübersicht

Hikal Limited produziert und verkauft zusammen mit seinen Tochtergesellschaften verschiedene chemische Zwischenprodukte, Spezialchemikalien und pharmazeutische Wirkstoffe an Pharma-, Tiergesundheits-, Biotech-, Pflanzenschutz- und Spezialchemieunternehmen in Indien, den Vereinigten Staaten, Kanada, Europa, Südostasien und auf internationaler Ebene.

Über das Unternehmen

HIKAL grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	2/6
Künftiges Wachstum	4/6
Vergangene Leistung	1/6
Finanzielle Gesundheit	4/6
Dividenden	3/6

Belohnungen

58.3% unter unserer Schätzung des beizulegenden Zeitwerts gehandelt

Prognostiziertes Gewinnwachstum 52.12% pro Jahr

Risikoanalyse

Zinszahlungen sind nicht ausreichend durch Erträge gedeckt

Die Dividende von 0.41% ist durch den Cashflow nicht ausreichend gedeckt.

Hikal Limited Wettbewerber

Supriya Lifescience

NSEI:SUPRIYA

₹50.5b

Aarti Drugs

BSE:524348

₹48.9b

Morepen Laboratories

BSE:500288

₹47.3b

Aarti Pharmalabs

NSEI:AARTIPHARM

₹57.7b

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für Hikal
Historische Aktienkurse
Aktueller Aktienkurs	₹382.85
52-Wochen-Hoch	₹410.90
52-Wochen-Tief	₹250.10
Beta	1.19
11 Monat Veränderung	17.01%
3 Monate Veränderung	13.27%
1 Jahr Veränderung	29.85%
33 Jahre Veränderung	-36.89%
5 Jahre Veränderung	158.94%
Veränderung seit IPO	2,534.29%

Aktuelle Nachrichten und Updates

Earnings Tell The Story For Hikal Limited (NSE:HIKAL) As Its Stock Soars 27%

Sep 13

We Think Hikal Limited's (NSE:HIKAL) CEO Compensation Package Needs To Be Put Under A Microscope

Sep 11

Recent updates

Earnings Tell The Story For Hikal Limited (NSE:HIKAL) As Its Stock Soars 27%

Sep 13

We Think Hikal Limited's (NSE:HIKAL) CEO Compensation Package Needs To Be Put Under A Microscope

Sep 11

Increases to CEO Compensation Might Be Put On Hold For Now at Hikal Limited (NSE:HIKAL)

Sep 16

Calculating The Fair Value Of Hikal Limited (NSE:HIKAL)

Mar 18

Hikal (NSE:HIKAL) Is Increasing Its Dividend To ₹1.20

Feb 16

Is Hikal (NSE:HIKAL) Using Too Much Debt?

Jan 13

With EPS Growth And More, Hikal (NSE:HIKAL) Is Interesting

Jun 01

We Think Hikal (NSE:HIKAL) Can Stay On Top Of Its Debt

May 17

An Intrinsic Calculation For Hikal Limited (NSE:HIKAL) Suggests It's 25% Undervalued

Mar 23

Does Hikal Limited (NSE:HIKAL) Have A Place In Your Dividend Portfolio?

Mar 10

If You Like EPS Growth Then Check Out Hikal (NSE:HIKAL) Before It's Too Late

Feb 23

Be Sure To Check Out Hikal Limited (NSE:HIKAL) Before It Goes Ex-Dividend

Feb 10

Is Hikal Limited's (NSE:HIKAL) Recent Stock Performance Influenced By Its Financials In Any Way?

Feb 05

Aktionärsrenditen

	HIKAL	IN Pharmaceuticals	IN Markt
7D	-3.8%	-1.8%	0.4%
1Y	29.8%	61.0%	43.9%

Rendite im Vergleich zur Industrie: HIKAL unter dem Niveau der Branche Indian Pharmaceuticals , die im vergangenen Jahr eine Rendite von 51.3% erzielte.

Rendite vs. Markt: HIKAL hinter dem Markt Indian zurück, der im vergangenen Jahr eine Rendite von 43.7 erzielte.

Preisvolatilität

Is HIKAL's price volatile compared to industry and market?
HIKAL volatility
HIKAL Average Weekly Movement	6.3%
Pharmaceuticals Industry Average Movement	6.1%
Market Average Movement	6.3%
10% most volatile stocks in IN Market	9.4%
10% least volatile stocks in IN Market	3.8%

Stabiler Aktienkurs: HIKAL hat in den letzten 3 Monaten keine nennenswerten Preisschwankungen aufgewiesen.

Volatilität im Zeitverlauf: HIKALDie wöchentliche Volatilität (4%) ist im vergangenen Jahr stabil geblieben.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
1988	2,061	Sameer Hiremath	www.hikal.com

Hikal Limited produziert und verkauft zusammen mit seinen Tochtergesellschaften verschiedene chemische Zwischenprodukte, Spezialchemikalien und pharmazeutische Wirkstoffe an Pharma-, Tiergesundheits-, Biotech-, Pflanzenschutz- und Spezialchemieunternehmen in Indien, den USA, Kanada, Europa, Südostasien und auf internationaler Ebene. Das Unternehmen ist in zwei Segmenten tätig: Pharmazeutika und Pflanzenschutz. Das Segment Pharmazeutika stellt pharmazeutische Wirkstoffe (APIs) her.

Hikal Limited's Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Hikal im Vergleich zum Marktanteil des Unternehmens?
HIKAL grundlegende Statistiken
Marktanteil	₹47.23b
Gewinn(TTM)	₹678.00m
Umsatz(TTM)	₹18.03b

69.7x

Kurs-Gewinn-Verhältnis

2.6x

Kurs-Umsatz-Verhältnis

Ist HIKAL zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
HIKAL Gewinn- und Verlustrechnung (TTM)
Einnahmen	₹18.03b
Kosten der Einnahmen	₹8.47b
Bruttogewinn	₹9.57b
Sonstige Ausgaben	₹8.89b
Umsatz	₹678.00m

Zuletzt gemeldete Gewinne

Jun 30, 2024

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	5.50
Bruttomarge	53.06%
Nettogewinnspanne	3.76%
Schulden/Eigenkapital-Verhältnis	68.8%

Wie hat sich HIKAL auf lange Sicht entwickelt?

Historische Performance und Vergleiche

Dividenden

0.3%

Aktuelle Dividendenrendite

21%

Ausschüttungsquote

HIKAL Aktienübersicht

Belohnungen

Risikoanalyse

Hikal Limited Wettbewerber

NSEI:SUPRIYA

₹50.5b

BSE:524348

₹48.9b

BSE:500288

₹47.3b

NSEI:AARTIPHARM

₹57.7b

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Hikal Limited Approves Interim Dividend and Declares Final Dividend for the Financial Year 2023-24

Earnings Tell The Story For Hikal Limited (NSE:HIKAL) As Its Stock Soars 27%

We Think Hikal Limited's (NSE:HIKAL) CEO Compensation Package Needs To Be Put Under A Microscope

Upcoming dividend of ₹0.60 per share

Hikal Limited, Annual General Meeting, Sep 17, 2024

Hikal Limited, Annual General Meeting, Sep 17, 2024

Recent updates

Hikal Limited Approves Interim Dividend and Declares Final Dividend for the Financial Year 2023-24

Earnings Tell The Story For Hikal Limited (NSE:HIKAL) As Its Stock Soars 27%

We Think Hikal Limited's (NSE:HIKAL) CEO Compensation Package Needs To Be Put Under A Microscope

Upcoming dividend of ₹0.60 per share

Hikal Limited, Annual General Meeting, Sep 17, 2024

Hikal Limited, Annual General Meeting, Sep 17, 2024

Hikal Limited Announces Management Changes

Price target increased by 14% to ₹398

First quarter 2025 earnings released: EPS: ₹0.41 (vs ₹0.56 in 1Q 2024)

Hikal Limited to Report Q1, 2025 Results on Aug 01, 2024

Hikal Limited's (NSE:HIKAL) Popularity With Investors Is Clear

Hikal Limited Approves Board Changes

New major risk - Revenue and earnings growth

Full year 2024 earnings released: EPS: ₹5.64 (vs ₹6.36 in FY 2023)

Hikal Limited Recommends Finally Dividend for the Financial Year 2023-2024

Hikal Limited to Report Q4, 2024 Results on May 09, 2024

Hikal Limited (BSE:524735) agreed to acquire 5.73% stake in FPEL Ujwal Private Limited for INR 41.2 million.

Investor sentiment improves as stock rises 16%

Less than half of directors are independent

Hikal Limited Announces Appointment of Dharmesh Panchal as the Chief Technology Officer

Upcoming dividend of ₹0.60 per share at 0.4% yield

Dividend of ₹0.60 announced

Third quarter 2024 earnings released: EPS: ₹1.31 (vs ₹2.14 in 3Q 2023)

Hikal Limited Declares Interim Dividend for the Financial Year 2023-2024, Payable on or Before March 9, 2024

Hikal Limited Announces Resignation of B. N. Kalyani as Director

Price target increased by 9.0% to ₹350

Second quarter 2024 earnings released: EPS: ₹1.02 (vs ₹2.01 in 2Q 2023)

Hikal Limited (BSE:524735) agreed to acquire 26% stake in Fpel Ujwal Private Limited for INR 41.2 million.

Price target increased by 10.0% to ₹353

Insufficient new directors

Hikal Limited Approves the Appointment of Berjis M Desai and V. Ramachandra Kaundinya as an Independent Director

Hikal Limited to Report Q2, 2024 Results on Nov 14, 2023

Hikal Limited, Annual General Meeting, Sep 26, 2023

Hikal Limited to Report Q1, 2024 Results on Aug 08, 2023

Hikal Limited Receives Communication from the Gujarat Pollution Control Board

A Look At The Fair Value Of Hikal Limited (NSE:HIKAL)

Hikal Limited Announces Recommendation of Final Dividend for the Financial Year 2022-23

Is Hikal (NSE:HIKAL) Using Too Much Debt?

Now 20% undervalued after recent price drop

Upcoming dividend of ₹0.60 per share at 0.5% yield

Hikal (NSE:HIKAL) Is Reducing Its Dividend To ₹0.60

Third quarter 2023 earnings released: EPS: ₹2.14 (vs ₹3.67 in 3Q 2022)

Hikal Limited Declares Interim Dividend for the Fiscal Year 2023, Payable on or Before March 3, 2023

Price target increased to ₹350

Investor sentiment improved over the past week

Founder & Executive Chairman recently bought ₹19m worth of stock

Hikal Limited (BSE:524735) acquired 26% stake in Radiance MH Sunrise Two Private Limited and Radiance MH Sunrise Four Private Limited for INR 46.2 million.

Investor sentiment improved over the past week

A Look At The Fair Value Of Hikal Limited (NSE:HIKAL)

Insufficient new directors

Second quarter 2023 earnings released: EPS: ₹2.01 (vs ₹3.57 in 2Q 2022)

Hikal Limited Approves Final Dividend for the Financial Year 2021-2022

Increases to CEO Compensation Might Be Put On Hold For Now at Hikal Limited (NSE:HIKAL)

Upcoming dividend of ₹0.40 per share

Insufficient new directors

Hikal Limited to Report Q3, 2023 Results on Feb 14, 2023

Investor sentiment improved over the past week

First quarter 2023 earnings released: ₹0.72 loss per share (vs ₹4.10 profit in 1Q 2022)

Hikal Limited to Report Q1, 2023 Results on Aug 10, 2022

Erträge & Einnahmen